<DOC>
	<DOCNO>NCT00486356</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , epirubicin , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose capecitabine give together epirubicin carboplatin treat patient progressive , unresectable , metastatic cancer .</brief_summary>
	<brief_title>Capecitabine , Epirubicin , Carboplatin Treating Patients With Progressive , Unresectable , Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine recommend phase II dose capecitabine give together epirubicin hydrochloride carboplatin patient progressive , unresectable , metastatic cancer . - Determine toxicity regimen patient . Secondary - Correlate end-of-infusion level epirubicin hydrochloride metabolites epirubicin hydrochloride dose clinical toxicity patient . - Correlate pharmacokinetics capecitabine clinical toxicity patient . - Determine possible correlation polymorphism promoter region thymidylate synthase gene clinical toxicity patient . - Document antitumor activity regimen patient . OUTLINE : This dose-escalation study capecitabine . Patients receive epirubicin hydrochloride IV 2 hour carboplatin IV 30 minute day 1 oral capecitabine twice daily day 2-5 , 8-12 , 15-19 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Peripheral blood collect pharmacokinetic pharmacogenetic study begin study treatment periodically study . Samples pharmacogenetic study analyze correlation polymorphism promoter region thymidylate synthase gene clinical toxicity . Patients also undergo bone marrow aspirate begin study treatment molecular profiling study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm cancer , meet 1 follow criterion : Disease progress standard therapy Locally advance unresectable primary recurrent solid tumor Metastatic disease , include previously untreated metastatic disease study regimen represent reasonable initial chemotherapy palliative intent ( e.g. , metastatic gastric cancer , hepatobiliary cancer , cancer effective standard therapy exist ) No potentially curative treatment option available ( e.g. , surgery , radiotherapy , chemoradiotherapy , combination chemotherapy ) No leukemia lymphoma No primary CNS malignancy CNS metastases PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 1.6 mg/dL Left ventricular ejection fraction ≥ 50 % No medical illness would preclude study treatment No active infection require IV antibiotic therapy unless infection resolve No history allergy platinum compound , mannitol , antiemetic appropriate administration conjunction protocoldirected chemotherapy No history unexpectedly severe intolerance fluorouracil Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No prior doxorubicin cumulative dos &gt; 300 mg/m² More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) immunotherapy At least 2 week since prior radiotherapy At least 8 week since prior strontium therapy At least 4 week since prior concurrent sorivudine brivudine No concurrent combination antiretroviral therapy HIVpositive patient No concurrent cimetidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
</DOC>